Venetoclax plus HMA for newly diagnosed AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two drugs, venetoclax and a hypomethylating agent (HMA), as the first treatment for adults with a type of leukemia called AML. The goal is to see if this combination works well and is safe for patients who have not had prior chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 50 years old.
- You have been diagnosed with AML (a blood cancer) that is not a specific subtype called APL.
- You have not received any previous chemotherapy for AML, except for a short course of hydroxyurea to control high white blood cell counts.
- You are in generally good health (able to do most daily activities) and your heart, liver, and kidney function are within acceptable limits.
- You are willing to give written consent and follow the study procedures, including bone marrow tests and follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
This early-phase trial tests whether azacitidine (CC-486) plus venetoclax can help people with acute myeloid leukemia (AML) that is not APL. It’s designed to find safe dosing and see how well the combination works for newly diagnosed or relapsed/refractory AML.
This trial tests a combination of two oral medicines (venetoclax and dexamethasone) for people with newly diagnosed AML who cannot have or choose not to have high-dose chemotherapy. The goal is to see if this gentler treatment is safe and tolerable.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
Hear when a new AML trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.